Azurity Pharmaceuticals announced that the FDA has approved Nymalize (nimodipine) oral solution in 30 mg/5 mL prefilled ENFit syringes for adult patients with subarachnoid hemorrhage. This new formulation aims to improve medication safety and reliability through standardized drug administration.
Enhanced Safety with ENFit Syringes
The prefilled ENFit syringes are designed to reduce the risk of misconnections between enteral devices and other medical devices, a problem that has led to reported injuries and deaths. The FDA has recommended the use of ENFit connectors to minimize these risks. Richard Blackburn, CEO of Azurity Pharmaceuticals, stated that delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure and reliable drug administration through standardization.
Clinical Indication and Availability
Nymalize is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of their post-ictus neurological condition. The medication is an alternative to capsule extraction for patients unable to swallow capsules. Azurity plans to make the prefilled ENFit syringes available for order through pharmaceutical wholesalers in the coming weeks. Nymalize is also available in prefilled oral syringes and 8 oz bottles.
Background on ENFit Adoption
ENFit connectors have seen increasing adoption in healthcare facilities, with approximately 60% of acute care facilities in the United States having already adopted them. This shift aims to replace traditional nasogastric tubing and reduce the potential for misconnections. From 2011 to 2018, the FDA received reports of 2 deaths, 24 serious injuries, and 32 device malfunctions related to enteral misconnections, though the agency believes many incidents go unreported.
